logo
  • 首页
  • 学术期刊
  • 论文检测
  • AIGC检测
  • 热点
  • 更多
    • 数据

Bisphosphonate labelling updates in Canada

被引:0
|
作者:
机构:
来源:
Reactions Weekly | 2012年 / 1384卷 / 1期
关键词:
Public Health; Osteoporosis; Bisphosphonate; Healthcare Professional; Femur Fracture;
D O I:
10.2165/00128415-201213840-00004
中图分类号:
学科分类号:
摘要:
引用
收藏
页码:2 / 2
相关论文
共 50 条
  • [31] Cross-Canada updates
    不详
    论文数: 0 引用数: 0 h-index: 0
    不详
    CANADIAN PHARMACISTS JOURNAL, 2021, 154 (01) : 16 - 18
  • [32] Cross-Canada updates
    不详
    论文数: 0 引用数: 0 h-index: 0
    不详
    CANADIAN PHARMACISTS JOURNAL, 2018, 151 (02) : 91 - 93
  • [33] FDA updates labelling for dronedarone with CV, death risk
    Reactions Weekly, 2012, 1383 (1) : 1 - 1
  • [34] ADR updates from Canada
    Reactions Weekly, 1998, 712 (1) : 3 - 3
  • [35] EMEA in favour of epoetin use, but recommends labelling updates
    Reactions Weekly, 2007, 1177 (1) : 4 - 4
  • [36] FDA announces approval of opioid analgesic labelling updates
    Reactions Weekly, 2023, 1988 (1) : 2 - 2
  • [37] HPRA: labelling updates for use of fluconazole during pregnancy
    Reactions Weekly, 2017, 1645 (1) : 4 - 4
  • [38] Evra labelling under review in Canada
    Reactions Weekly, 2005, 1080 (1) : 3 - 3
  • [39] Labelling for aripiprazole products updated in Canada
    Reactions Weekly, 2015, 1577 (1) : 3 - 3
  • [40] Revised labelling for Adderall XR in Canada
    Reactions Weekly, 2005, 1068 (1) : 2 - 2
← 12345 →